Cancer gene discovery in hepatocellular carcinoma

Lars Zender1,2, Augusto Villanueva3, Victoria Tovar3, Daniela Sia3, Derek Y. Chiang4, Josep M. Llovet3,5,6,

1Helmholtz Centre for Infection Research, Braunschweig 38124, Germany; 2Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover 30625, Germany; 3HCC Translational Research Laboratory, Barcelona-Clinic Liver Cancer Group, Liver Unit, Institut d’Investigacions Biomèdiques Agustí Pi i Sunyer [IDIBAPS], Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas [CIBEREHD], Hospital Clinic, Catalonia, Spain; 4Department of Genetics and UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; 5Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA; 6Institució Catalana de Recerca i Estudis Avançats, Catalonia, Spain

Hepatocellular carcinoma (HCC) is a deadly cancer, whose incidence is increasing worldwide. Albeit the main risk factors for HCC development have been clearly identified, such as hepatitis B and C virus infection and alcohol abuse, there is still preliminary understanding of the key drivers of this malignancy. Recent data suggest that genomic analysis of cirrhotic tissue – the pre-neoplastic carcinogenic field – may provide a read-out to identify at risk populations for cancer development. Given this contextual complexity, it is of utmost importance to characterize the molecular pathogenesis of this disease, and pinpoint the dominant pathways/drivers by integrative oncogenomic approaches and/or sophisticated experimental models. Identification of the dominant proliferative signals and key aberrations will allow for a more personalized therapy.

Pathway-based approaches and functional experimental studies have aided in identifying the activation of different signaling cascades in HCC (e.g. epidermal growth factor, insulin-like growth factor, RAS, MTOR, WNT-β-catenin, etc.). However, the introduction of new high-throughput genomic technologies (e.g. microarrays, deep sequencing, etc.), and increased sophistication of computational biology (e.g. bioinformatics, biomodeling, etc.), opens the field to new strategies in oncogene and tumor suppressor discovery. These oncogenomic approaches are framed within emerging disciplines such as systems biology, which integrates multiple inputs to explain cancer onset and progression. In addition, the consolidation of sophisticated animal models, such as mosaic cancer mouse models or the use of transposons for mutagenesis screens, have been instrumental for the identification of novel tumor drivers. We herein review some classical as well as some recent fast track approaches for oncogene discovery in HCC, and provide a comprehensive landscape of the currently known spectrum of molecular aberrations involved in hepatocarcinogenesis.

© 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Overview

Hepatocellular carcinoma (HCC) represents a major health problem worldwide [1]. Despite its global importance, liver cancer is understudied compared to other major lethal cancers, and hence, our knowledge of the genomic alterations implicated in HCC initiation and progression is still fragmentary. This is partly due to the high complexity and heterogeneity of HCC cancer genomes, which hamper a straightforward identification of new cancer genes by genomic approaches alone. There is also only a limited arsenal of model systems available to study the development of the disease, and to test potential intervention strategies. In this scenario, HCC is probably one of the tumor types where a more complete understanding of the underlying genetic alterations could have a major impact on the development of new treatment strategies. Because of their therapeutic relevance as potential new targets, this review will first summarize the current knowledge of signaling pathways in HCC. Next, we will briefly comment the role of P53 due to its paradigmatic role as a tumor suppressor in HCC, identified using a gene-based approach. Finally, we will discuss new integrative oncogenomic approaches for an accelerated cancer gene discovery in HCC.

Signaling pathways in hepatocellular carcinoma

Activation of several signaling pathways, both in cirrhotic tissue and in overt HCC, has been implicated in human hepatocarcinogenesis [2] (Fig. 1). Their relevance resides in their capacity to act as targets for new therapies. In fact, activation of RAS/MAPK and VEGF signaling (i.e. angiogenesis) in HCC stimulated initial
evaluations of the multi-kinase inhibitor sorafenib for the treatment of human HCC. As a result of recent positive investigations, sorafenib is currently the sole systemic therapy approved for the treatment of advanced HCC [3,4].

Proliferation signaling pathways

Epidermal growth factor (EGF) signaling is one of the most thoroughly evaluated signaling cascades in human HCC. Robust data demonstrate its activation in a subset of HCC, up-regulation of EGF being one of its mechanisms of activation [5]. Genetic evidence was also provided by a recent study showing gains of chromosome 7 in human HCC, where EGFR is located [6]. Some complementary evidence points to EGF as a key driver in HCC. A case-control study identified a significant increase in HCC risk associated with a specific single nucleotide polymorphism (SNP) of the EGF gene [7]. Interestingly, the same investigation showed that this SNP increased EGF mRNA stability in cell lines; thus, markedly enhancing signaling through the EGF receptor (EGFR). Additionally, EGF was ranked among the top up-regulated genes included in a gene signature that was able to identify HCC patients treated with surgical resection at high risk of developing a late recurrence (de novo HCC) [8]. Unsuspected mutagenic screening in mice also detected EGFR as a relevant gene during HCC development [9]. There are some consistent data regarding a selective EGF-blockade in experimental models. Gefitinib, an EGFR tyrosine kinase inhibitor, was able to significantly decrease HCC incidence in a genotoxic model of HCC [10]. Another study showed anti-proliferative and pro-apoptotic effects following EGFR blockade in human HCC xenografts [2]. In addition, robust evidence suggests the prominent role of TGFA as a major paracrine activator of EGF signaling in HCC [11]. TGFA contributes to proliferation and the invasion phenotype of tumor cells, and it has been shown to generate liver tumors upon co-activation with other oncogenes in animal models [e.g. double-transgenic mice: MYC/TGFA] [12]. Finally, preliminary data obtained in phase II clinical trials using an EGFR specific inhibitor (i.e. erlotinib) in HCC [13,14], are currently being expanded into phase III investigations.

The insulin-like growth factor (IGF) signaling system is an essential regulator of growth and development [15]. The biological actions of the axis comprise a complex network of molecules whose main components are two high-affinity mitogenic ligands: IGF1 and IGF2. The type 1 IGF receptor (IGF1R) has tyrosine kinase activity, the type 2 IGF receptor (IGF2R) is involved in the internalization and degradation of IGF2, and at least six high-affinity IGF–binding proteins (IGFBPs) which modulate the amount and bioactivity of locally available IGFs. Despite its role in normal physiology, the IGF axis is involved in the pathogenesis of several human malignancies, including breast, colon, prostate, lung, and liver [16]. In HCC, the most frequently described aberrant feature concerning this pathway is over-expression of IGF2, even found in pre-neoplastic lesions [11]. This mitogen, highly expressed during embryonic development, is strongly down-regulated after birth due to tight epigenetic regulation of the P2-P4 fetal promoters. Reactivation of IGF2 expression involves loss of specific imprinting and hypomethylation [17]. Allelic losses of IGF2R have been detected in 60–70% of HCC, being inactivating
MTOR is one of the most important molecules downstream of AKT after surgical resection in a large cohort of Japanese patients [28]. RAS mutations in HCC are found at low frequency [29].

Growth factor receptor activation that in turn activates RAF, MEK, and ERK. The RAS cascade transduces extracellular signals initiated by growth factor receptor blockade in experimental models [31]. There is no pure anti-RAS therapy approved, and only sorafenib has shown some effective signaling blockage, albeit there is no approved drug so far. Moreover, there is compelling evidence of anti-neoplastic activity (i.e., decreased proliferation, survival, and invasion as well as delayed tumor growth in xenograft models [23]). MET activation in cancer may occur by several mechanisms including ligand-receptor autocrine stimulation, somatic and germ-line mutations, or MET amplification, allowing MET activation even in the absence of HGF [24].

In HCC, several investigators identified over-expression of MET (20–48%) when compared to surrounding non-tumorous tissue. For example, a study found a correlation between MET over-expression and a higher incidence of intrahepatic metastasis, as well as a reduced survival following tumor resection [25]. By contrast, decreased HGF expression has been reported in HCC [25], suggesting a marginal role for HGF in this malignancy. A recent study took advantage of a comparative functional genomics approach on 242 HCC samples for identifying a gene signature correlated with HCC metastatic potential. This signature included genes associated with oxidative stress, cell motility, cytoskeletal organization, and angiogenesis [26]. Overall, MET has emerged as a very attractive target for anticancer therapies, albeit there is no approved drug so far. Moreover, there is compelling evidence of anti-neoplastic activity (i.e., decreased proliferation, migration and invasion) following MET down-regulation in experimental models of HCC [27].

Upon EGFR, IGFR or MET activation, extracellular signals can be transduced through either AKT or MAPK signaling pathways. Molecules belonging to both signaling cascades (e.g., AKT or KRAS) have been identified as bona fide oncogenes in human cancer. The RAS cascade transduces extracellular signals initiated by growth factor receptor activation that in turn activate RAF, MEK and ERK and result in proliferative and anti-apoptotic signals [28]. RAS mutations in HCC are found at low frequency [29]. Interestingly, recent studies show frequent over-expression of RAS in human HCC [30,31]. In addition, down-regulation of RAS negative regulators has been reported, such as hypermethylation of the RAS association family 1 gene A (RASSF1A) and its homologue NORE1A [30]. There is no pure anti-RAS therapy approved, and only sorafenib has shown some effective signaling blockade, either alone or in combination with rapamycin (RAS and MTOR blockade in experimental models) [31].

AKT has been described as a predictor of tumor recurrence after surgical resection in a large cohort of Japanese patients [32], suggesting a possible implication in the invasive phenotype. MTOR is one of the most important molecules downstream of AKT.

Pathways involved in liver development and cell differentiation

The ultimate identity of the specific target cell for transformation in HCC is still elusive [37]. Despite recent progresses, the involvement of altered embryonic cellular features such as self-renewal, plasticity, asymmetric division, pluripotency and cellular fate in human cancer remains enigmatic [38]. In accordance with the cancer stem cell hypothesis, a number of studies found dysregulation of pathways involved in cellular differentiation in HCC, such as the WNT canonical pathway. Besides its role in liver development and differentiation [39,40], WNT signaling has also been implicated in cell proliferation and metabolism [41]. Unlike colon cancer, APC mutations are infrequent in HCC, whereas CTNNB1 and AXIN1 mutations are frequently found in HCC [2]. Mutations prevent β-catenin ubiquitination and subsequent degradation. Nuclear accumulation of β-catenin induces transcription of several genes related to cell differentiation and proliferation. In addition, unsupervised clustering of gene expression data from two different studies enabled the identification of a subclass of patients characterized by activation of genes related to WNT signaling [6,42]. Hence, there is enough evidence to assume the implication of this signaling cascade in HCC, although it is still unknown whether non-canonical activation of this pathway may also be relevant during human hepatocarcinogenesis. There are currently several efforts evaluating different blockade strategies for the WNT pathway, stabilization of AXIN being one of the most promising [43]. Nevertheless, there are no clinical trials in late phases evaluating selective blockade of any of its components.

Another pathway involved in proliferation control that is found abnormally activated in HCC is the Hedgehog signaling pathway (HH). This cascade is structurally very similar to WNT, although different mechanisms account for the dysregulation of HH. Over-expression of Sonic or Indian ligands, and/or inactivation of a tumor suppressor, the HH inhibitory protein, have been identified as responsible for HH activation in experimental models of HCC as well as in human samples [44,45]. Several HH inhibitors are currently under preclinical evaluation in HCC.
Review

Pathways involved in inflammation

The role of cascades involved in inflammation has been described in early stages of the disease. Inflammation is a hallmark of liver cirrhosis, and hence, several inflammation-related pathways have been evaluated as potential targets for HCC chemoprevention. In a recent large clinical study (n = 1005), anti-viral therapies with interferon failed to show efficacy in terms of HCC-prevention in patients with hepatitis C-related liver disease who did not respond to conventional anti-viral therapies [46]. Nonetheless, other information pinpoints interleukin-6 (IL-6) signaling as an appealing target for HCC-prevention. IL-6, a multifunctional cytokine with different functions in the immune system, justifies gender disparities in HCC incidence (i.e. much higher incidence rate in males than females [47]). Estrogens suppress IL-6 production and therefore limit chemically induced liver carcinogenesis.

Enrichment in IL-6 downstream signals has also been found in a gene signature associated with poor survival and de novo tumor formation in patients with HCC treated with surgical resection [8]. Additionally, a recent report identified IL-6 signaling through STAT3 as a major pathway in maintaining stem cell like features in HCC [48], highlighting the potential role of this cascade as a novel target in cancer stem cell renewal. Currently, different anti-IL-6 humanized monoclonal antibodies are under evaluation in inflammatory conditions, but their role in HCC is yet to be determined. There is some degree of crosstalk between IL-6 and TGFβ signaling, a pleiotropic pathway with potentially antagonistic actions. Comparative functional genomics have allowed the identification of a subgroup of HCC patients with a significant enrichment in late responsive TGFβ genes. Thus patients expressing these genes also had more invasive tumors and poor survival [49]. All these data have encouraged efforts aiming to modulate TGFβ signaling, in part due to its clear involvement in metastasis. Downstream of IL-6, signals can be transduced through the JAK/STAT signaling cascade. Nuclear localization of STAT3 results in trans-activation of its target genes (e.g. protein inhibitors of activated STATS [PIAS], the SH2-containing phosphatases [SHP], and the suppressors of cytokine signaling [SOCS]), implicated in cell growth, proliferation, differentiation and survival. Constitutive activation of JAK/STAT has been detected in a subset of HCC, mostly due to promoter methylation of STAT inhibitors such as CIS, SOCS-1, SOCS-2, SOCS-3, and SHP1 [30]. Additionally, treatment with de-methylating agents resulted in growth suppression and strongly induced apoptosis in HCC cell lines [30].

There is strong evidence suggesting a linking role of the NF-Kappaβ cascade in inflammation and liver oncogenesis [50]. Recent progress regarding drug-mediated inhibition of this pathway provides new perspectives for primary prevention strategies in cirrhotic patients. AEG1 has been identified as a downstream molecule in this pathway, and could also act as a novel molecular target in this setting [51]. Additionally, aberrant activation of the lymphotoxin pathway in mice livers recapitulates the stages of fibrosis and inflammation that precedes human liver cancer, providing a novel family of potential therapeutic targets [52,53].

Pathways involved in neoangiogenesis

High vascularity is a hallmark of human HCC. Tumor cells release pro-angiogenic factors in response to hypoxic conditions and nutrient deprivation and thus activate endothelial cells. Multiple preclinical studies have revealed vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs) as major drivers underlying pro-angiogenic signals in human HCC. VEGF is considered the most potent angiogenic factor in HCC, and it is often found over-expressed in tumor specimens, as well as its receptors VEGFR-1 and VEGFR-2. Moreover, high VEGF expression levels have been consistently associated with a more aggressive disease [54], and VEGF serum levels have also been identified as a predictor of poor prognosis after resection [55]. The FGF receptor family includes 4 transmembrane receptors (FGFR-1–4) and 1 soluble receptor (FGFR5) and at least 23 known ligands. There is evidence that links FGF signaling dysregulation and malignant transformation of several cancers. In HCC, clinical studies have shown over-expression of FGFRs in human samples and correlation with tumor angiogenesis [56]. Several studies have reported crosstalk between FGF and VEGF signaling, indicating a possible synergistic effect of both cascades promoting angiogenesis [57]. Besides these pathways, angiopoetins (Ang) have also been involved in normal and aberrant vascular formation through its interaction with the receptor Tie-2. Despite recent controversial data, Ang-2 has been described as a promoter of tumor angiogenesis in HCC, particularly in the presence of VEGF [58]. Finally, experimental models have suggested a role for another pro-angiogenic cascade, platelet derived growth factor (PDGF) signaling, in HCC development [59]. Indeed, PDGF receptor-C transgenic mice developed fibrosis and HCC with long latency [60]. Results of the recently published phase III clinical trial with sorafenib (i.e. B-Raf, VEGFR and PDGFR inhibitor) further suggest an important role of anti-angiogenic agents in the therapeutic management of HCC [4].

The P53 tumor suppressor

The P53 tumor suppressor has been found mutated in more than 50% of all human tumors. Owing to its role in preserving genetic stability, P53 was designated as the guardian of the genome. Upon DNA damage inducing cellular stresses, P53 becomes activated and prevents further damage and oncogenic transformation by either triggering apoptosis or by inducing a transient cell cycle arrest to allow DNA repair [61]. The p53 protein is a tetrameric transcription factor, and, in addition to its roles in apoptosis- and cell cycle regulation, P53 was shown to impact cellular differentiation, developmental processes and senescence. Over the past couple of years it was shown that P53 plays a major role in hepatocarcinogenesis. Strikingly, there is a high variability in the frequency of P53 mutations and its mutational spectrum in different geographical areas. In areas with high Aflatoxin B1 food contamination (sub-Saharan Africa and China) there is a high percentage of HCCs revealing a recurrent point mutation at the third position of codon 249 resulting in a G:C to T:A transversion [62]. Interestingly, it was shown that the 249Ser mutation is an early event in AFB1-induced hepatocarcinogenesis, with a high frequency of 249Ser mutations already being found in non-tumoral regions of livers with chronic AFB1 exposure [62]. In strong contrast, P53 mutations are believed to represent a late, progression-associated event in hepatocarcinogenesis. Interestingly in non-ABF1 related HCCs. For example, different P53 mutations have been found in nodules in HCCs leading to disease progression, and overall P53 mutations are preferentially found in less differentiated HCCs. One major risk factor for the development of hepatocellular carcinoma is chronic infection with hepatotropic viruses like hepatitis B and...
C. Different viral proteins have been shown to impact hepatocarcinogenesis in experimental systems. In the past couple of years, a lot of attention was paid to the hepatitis B virus X protein (HBx), one of the most frequently integrated viral genes in the host genome [63,64]. Besides many other functions, HBx was shown to bind P53 and to block P53 sequence specific DNA-binding and P53 dependent transcription, being ultimately capable of blocking P53-mediated apoptosis.

Cancer genome screening and validation strategies

Current efforts in cancer gene discovery mostly rely on genomic approaches alone. Recent advances in genome scanning technologies have enabled to examine cancer genomes at a high-resolution, thus making it feasible to catalogue every gene whose mutation occurs in human cancer [65]. Regions of copy number alteration can be identified by high-resolution array-based comparative genomic hybridization (CGH) or SNP arrays. Regions of chromosomal amplification mostly harbor oncogenes whereas deleted regions contain tumor suppressor genes [66]. In addition, high-throughput sequencing technologies are available for detection of somatic point mutations selected during tumor evolution [67,68]. However, such approaches are expensive and yield candidates based on statistical criteria only. The situation is even more complicated because due to genomic instability, gene linkage and spontaneous mutagenesis, cancers also contain many passenger mutations that are not contributing to the tumor phenotype. Moreover, it is difficult to pinpoint relevant tumor suppressors in large deletions, as some genes are haploid sufficient tumor suppressors, so that loss of even one allele can promote tumorigenesis, even without a corresponding mutation in the remaining wild-type allele. In conclusion, candidate genes identified through genomic approaches require stringent functional validation before expensive drug development efforts can be justified. In this regard, functional characterization of cancer genes is often a tedious process, and it is not always obvious which assays will reveal the putative oncogenic activity of a previously uncharacterized gene. Furthermore, although cell culture systems are fast and tractable, they do not recapitulate important factors like the tumor microenvironment, and consequently, they do not allow surveying all relevant gene activities.

For proving new candidate cancer genes it has become gold standard to generate transgenic and knockout mice, and to study the respective genes in a relevant context in vivo [69]. Importantly, as such genetically engineered mouse models (GEMM) allow to generate a detailed map of the route taken by the tumor cell to reach its destination, cancer mouse models are suitable for modeling intermediate stages of tumor formation, which is essential for a complete understanding of the disease and for the development of new treatment strategies. This is in strong contrast to the traditional studies of human cancers, which only provide a snapshot of the final result. GEMM also play an important role in preclinical drug testing, as it is becoming more evident that subcutaneously grown tumors in immunodeficient mice, which were derived from cultured tumor cell lines, may not predict the treatment responses of human tumors, and may hence contribute to the high numbers of ineffective compounds entering clinical trials [70].

Over the last years, GEMM have provided elegant and powerful approaches to validate potential oncogene and tumor suppressor genes in HCC (Table 1A) [12,60,71–90]. Currently, mouse models of liver cancer are based mainly on classic transgenic approaches, tetracycline-regulated transgene expression or chemically induced carcinogenesis (thoroughly reviewed elsewhere [91]). These models have provided important insights into the molecular mechanisms of hepatocarcinogenesis, although, they have several limitations. First, the use of tissue-specific promoters generates a bias towards certain epithelial cells and may thus alter the cell of origin. Furthermore, the homogeneous expression of an oncogene (or deletion of a tumor suppressor gene) in all cells within a tissue creates a field effect such that all cells have altered gene expression, a situation that clearly does not mimic the situation of spontaneous tumorigenesis in humans. Secondly, it is very cost and time-intensive to generate germ-line transgenic and knockout animals, and production of compound mutant animals can involve complicated intercrossing strategies that are extremely slow. Thirdly, germ-line transmission of transgenes or targeted knock-out alleles in some cases produce prenatal abnormalities resulting in embryonic lethality or developmental compensation in the resulting tissue.

A strategy that addresses some of the problems with germ-line transgenic mice is the use of so called chimeric mouse models, which are based on the genetic manipulation and retransplantation of stem or progenitor cells. Such models were initially developed for studying hematopoietic malignancies and have proven very successful to get new insights into mechanisms of tumor initiation, progression and treatment response in blood cancer [92–95]. More recently such models were also developed for the study of HCC [73,96]; these mosaic HCC mouse models are based on the ex-vivo manipulation of liver progenitor cells followed by the seeding of these cells into normal recipients. They allow studying compound genetic lesions in HCC at a fraction of the time that would be needed when using standard transgenic or knockout approaches.

Integrative oncogenic approaches for accelerated cancer gene discovery in HCC

To speed up the process of cancer gene discovery in HCC, recent studies took advantage of integrative approaches, where oncogenic analyses of human HCC were coupled with screening approaches in innovative mosaic cancer mouse models. The most relevant validated examples are summarized in Table 1B [9,51,72,73,97]. For example, high-resolution array-CGH profiling of progenitor cell derived murine HCCs of the genotype c-MYC; P53—/—, revealed that these tumors spontaneously acquire genomic amplification of the 9qA1 chromosomal region, which is syntenic to the human 11q22 region. Interestingly, this region has been found amplified in different human tumors. Delineation of the minimal region of overlap between human and mouse HCCs and subsequent analyses of expression levels for all genes embedded in the overlapping region, pinpointed cIAP1 and YAP as potential driver genes of the 11q22 amplicon in human HCC. Interestingly, when both genes were functionally tested in the mouse model, they did not only accelerate hepatocarcinogenesis individually, but also showed a strong collaboration to accelerate the development of liver tumors. Therefore, these genes were validated as new oncogenes in HCC and were found to be co-driver genes of the 11q22 amplicon [98]. Importantly, a subsequent study reported the expression of the YAP oncogene as an independent prognostic factor in human HCC [98].
**Table 1. Relevant oncogenes and tumor suppressor genes identified through (A) selective dysregulation in animal models, or through (B) functional oncogenomic approaches.**

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Oncogene/Tumor suppressor gene</th>
<th>Biological activity/Pathway</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYC</td>
<td>Oncogene</td>
<td>Proliferation control</td>
<td>[12,71–73]</td>
</tr>
<tr>
<td>EGF</td>
<td>Oncogene</td>
<td>EGFR signaling</td>
<td>[78]</td>
</tr>
<tr>
<td>TGFα</td>
<td>Oncogene</td>
<td>EGFR signaling</td>
<td>[12,77]</td>
</tr>
<tr>
<td>CTNNB1</td>
<td>Oncogene</td>
<td>Wnt-signaling</td>
<td>[75,79]</td>
</tr>
<tr>
<td>APC</td>
<td>Tumor suppressor gene</td>
<td>Wnt-signaling</td>
<td>[74,80]</td>
</tr>
<tr>
<td>PTEN</td>
<td>Tumor suppressor gene</td>
<td>PI3K/Akt/mTOR signaling</td>
<td>[76,80]</td>
</tr>
<tr>
<td>AKT</td>
<td>Oncogene</td>
<td>PI3K/Akt/mTOR signaling</td>
<td>[73]</td>
</tr>
<tr>
<td>HGF</td>
<td>Oncogene</td>
<td>Growth factor</td>
<td>[81,82]</td>
</tr>
<tr>
<td>MET</td>
<td>Oncogene</td>
<td>Growth factor receptor</td>
<td>[83,84]</td>
</tr>
<tr>
<td>PDGFR</td>
<td>Oncogene</td>
<td>Growth factor receptor</td>
<td>[60]</td>
</tr>
<tr>
<td>BAS (NRAS, HRAS)</td>
<td>Oncogene</td>
<td>Ras/MAPK signaling</td>
<td>[71,73,75,85]</td>
</tr>
<tr>
<td>PS3</td>
<td>Tumor suppressor gene</td>
<td>Stress response, cell cycle inhibition</td>
<td>[73,86]</td>
</tr>
<tr>
<td>EZF1</td>
<td>Oncogene</td>
<td>Cell cycle</td>
<td>[87]</td>
</tr>
<tr>
<td>CCND1</td>
<td>Oncogene</td>
<td>Cell cycle</td>
<td>[88,89]</td>
</tr>
<tr>
<td>Telomerase</td>
<td>Oncogene</td>
<td>Cell senescence</td>
<td>[90]</td>
</tr>
</tbody>
</table>

**A) Long established HCC cancer genes which have been functionally validated in vivo**

The discovery of RNA-interference has revolutionized “loss of function genetics”. RNAi-based delivery strategies have shown antitumoral activity in animal models of HCC [99], and dysregulation of miRNA have also proved high prognostic predictive value in this disease [100]. It was recently shown that stable RNAi can be efficiently used in mosaic cancer mouse models [73,80,101]. For example, the use of stable RNAi in murine hepatocarcinomas that bore the clpA1 and YAP embedding 9gA1 amplicon quickly allowed the validation of these genes as bona fide tumor suppressor genes. The top-scoring candidate tumor suppressor from the screen, exportin 4, mediates the nuclear export of SMAD3, EIF5A1, and EIF5A2. XPO4 loss seems to be pro-tumorigenic by promoting the nuclear accumulation of its key substrates. Interestingly, XPO4 deletions are relatively common, thus suggesting that this may be an important mechanism of oncogenesis. It was observed that suppression of XPO4 stimulates TGF-β signaling [80], which can promote invasion and metastasis in late stage liver cancer. Similarly, EIF5A2 over-expression occurs in many tumor types [103] and it could be demonstrated that XPO4 loss enhances proliferation through EIF5A2, which is per se oncogenic in mice [80]. Importantly, the XPO4-EIF5A2 signaling circuit appears relevant in HCC and other tumor types.

**B) HCC cancer genes recently identified and validated through integrative functional genomics**

The top-scoring candidate tumor suppressor from the screen, exportin 4, mediates the nuclear export of SMAD3, EIF5A1, and EIF5A2. XPO4 loss seems to be pro-tumorigenic by promoting the nuclear accumulation of its key substrates. Interestingly, XPO4 deletions are relatively common, thus suggesting that this may be an important mechanism of oncogenesis. It was observed that suppression of XPO4 stimulates TGF-β signaling [80], which can promote invasion and metastasis in late stage liver cancer. Similarly, EIF5A2 over-expression occurs in many tumor types [103] and it could be demonstrated that XPO4 loss enhances proliferation through EIF5A2, which is per se oncogenic in mice [80]. Importantly, the XPO4-EIF5A2 signaling circuit appears relevant in HCC and other tumor types.
It is noteworthy that most of the identified genes have never been linked to cancer before. Examples for identified genes are an FGF (FGF6), an RNA helicase (DDX20/GEMIN3), a metabolic enzyme (GL01), and CJD4 (CX40.1), a gap junction protein. Functional validation assays show that apparently all these genes act as tumor suppressors in vivo. Some of the genes, for example FSTL5, NRSN2 (C200RP38), and ZBX6 (FLJ2049), are largely uncharacterized, however, based on the functional data obtained from the mouse model and on the notion that all of them were found somatically altered in human cancer, these genes very likely represent important tumor suppressor genes in HCC. It is obvious that more work will be required to understand how each of these genes suppresses tumorigenesis, and, given the unexpected nature of each gene, such studies may uncover new pathways or principles relevant to human HCC. Some of the identified genes point towards new strategies for cancer therapy. For example, FGF6 and FSTL5 encode secreted proteins whose systemic administration might restore tumor suppressor function and serve as new biological anti-cancer therapies.

The described results establish the feasibility of performing functional in vivo RNAi screens and illustrate how combining cancer genomics, RNAi and mosaic mouse models can facilitate the functional annotation of the cancer genome (Fig. 2). Such integrative approaches may complement existing large-scale approaches like the human cancer genome project. Another appealing example for in vivo screening approach to identify new cancer genes in HCC was recently demonstrated by Keng et al. [9]. In their study the authors used a liver directed insertional mutagenesis screen, which was accomplished by hepatocyte-specific expression of a mutagenic transposon to screen for new cancer genes in HCC. This screen was performed either in a wild type or in a sensitized background with a mutant p53 allele. In both backgrounds, pre-neoplastic nodules could be detected starting 160 days after liver-specific activation of the mutagenic transposon. The vast majority of animals only contained pre-neoplastic nodules or hepatic adenomas, but in some animals (>440 days of age) also full-blown liver carcinomas were found. Using pyrosequencing, the authors identified common insertion sites in the genomic DNA from enucleated pre-neoplastic foci. A total of 19 common insertion sites were identified and two affected genes were chosen for functional validation, UBE2H and a truncated EGRF. While definite experimental evidence that these genes cause HCC is still missing, the authors were able to show that over-expression of the candidate oncogene UBE2H accelerates proliferation of murine hepatoma cell line in vitro. The truncated EGRF was functionally tested resulting in the development of pre-neoplastic lesions in re-populated mouse livers. While the long latency until tumor development and the low penetrance to full blown HCC certainly represent limitations of the model, it is yet noteworthy that some of the 19 candidate HCC cancer genes could be found altered in recently published datasets of human HCC. Therefore, it will be of high interest to subject these candidate genes to thorough functional validation in different HCC mouse models to ultimately probe their contribution to the development of HCC.

With the advent of novel high-throughput technologies, such as deep sequencing and integrative genomic analysis, and the consolidation of sophisticated animal models, such as mosaic cancer mouse models or the use of transposons for mutagenic screening, we are at the dawn of a new era in cancer gene discovery. These technologies are identifying novel oncogenes and tumor suppressor genes, which along with the already known drivers obtained from classical GEMM (Table 1) will provide a more comprehensive picture of the key molecular alterations of liver cancer.

Conflicts of interest

The Authors who have taken part in this study have declared a relationship with the manufacturers of the drugs involved. Josep Llovet has grants from the National Institute of Health –NIDDK 1R01DK076986-01, National Institute of Health (Spain) grant I+D Program (SAF-2007-61898) and Samuel Waxman Cancer Research Foundation, and the HCC Consortium are recipients of the AACR-Landon Innovator International award. Dr Llovet has consultancy agreements with Bayer Healthcare, BMS, Biocompaticles, and is currently receiving funding for research from Bayer Healthcare, BMS and Johnson & Johnson.

Lars Zender is supported by grants from the German Research Foundation [Emmy Noether Programme] and grants from the Helmholtz Association of German Research Centers (“Helmholtz Impuls und Vernetzungsfond”). Augusto Villanueva is supported by an EASL–Sheila Sherlock Fellowship.

References


